# NEXUS-OPS — Phase 5 Final Scientific & Technical Audit
**Project:** IBM Quantum Qiskit Fall Fest 2026 | Project Q | PS-Q1 Biomedical Classifier  
**Milestone:** Phase 5 — Quantum Machine Learning (VQC Architecture & Evaluation)  
**Auditor:** Senior Quantum Machine Learning & Software Integrity Auditor  
**Date:** 2026-10-13  
**Status:** FULLY VERIFIED & APPROVED FOR PHASE 6 TRANSITION  

---

## 1. Scope of Audit

This audit evaluates the complete Phase 5 engineering and experimental workflow, covering:
1. **Source Code Implementation:** `src/vqc_circuit.py`, `src/vqc_preprocessing.py`, `src/vqc_training.py`, `src/vqc_evaluation.py`.
2. **Experimental Results & Artifacts:**
   - `results/vqc_training_runs.json` (10 training runs across 2 folds and 5 seeds)
   - `results/vqc_loro_summary.json` (Statistical aggregation across folds and seeds)
   - `results/vqc_model_selection.json` (Cross-validation ranking and frozen winner)
   - `results/vqc_heldout_evaluation.json` (Held-out evaluation on Records 200 & 208)
3. **Data Governance & Zero Leakage Compliance:** Validation of train/test boundary and parameter freezing.
4. **Reproducibility & Statistical Reporting:** Verification of numerical metrics and convergence claims.

---

## 2. Compliance Checklist & Audit Findings

### 2.1 Frozen Architectural Decisions (D1–D10)
| Decision ID | Constraint Description | Implementation Status | Audit Finding |
| :---: | :--- | :---: | :---: |
| **D1** | 6 logical qubits matching 6 biomedical features | **PASS** | Exact match in `src/vqc_circuit.py` (`NUM_QUBITS = 6`) |
| **D2** | First-order $R_y$ angle encoding | **PASS** | $R_y(x_i)$ applied to qubit $i$, bounded in $[0, \pi]$ |
| **D3** | `RealAmplitudes` ansatz (reps=1, linear entanglement) | **PASS** | 12 parameters, exactly 5 CX gates in linear topology |
| **D4** | Ensemble average Pauli-$Z$ observable $\hat{O} = \frac{1}{6} \sum Z_i$ | **PASS** | Verified in `build_ensemble_z_observable()` |
| **D5** | Readout probability mapping $p = (E+1)/2$ | **PASS** | Implemented with NaN/inf and boundary validation |
| **D6** | Decision threshold $\tau = 0.5$ ($p < 0.5 \rightarrow \text{Normal}$, $p \ge 0.5 \rightarrow \text{VEB}$) | **PASS** | Maintained consistently across all evaluation routines |
| **D7** | Brier score / MSE loss objective | **PASS** | Implemented as $\frac{1}{N}\sum(p_k - y_k)^2$ |
| **D8** | COBYLA derivative-free optimizer | **PASS** | SciPy PRIMA COBYLA with `rhobeg=0.5` |
| **D9** | Protocol A LORO cross-validation on Records 106 & 119 | **PASS** | Strict record-isolated train/validation splits |
| **D10** | Quarantined held-out test cohort (Records 200 & 208) | **PASS** | Quarantined until formal pre-freeze documentation |

### 2.2 Data Governance & Zero Leakage Audit
- **Pre-Processing Scaler Fit:** Scaler parameters (`data_min_`, `data_max_`, `scale_`) were computed strictly on the training partition (`features_train.csv`). The held-out test cohort (`features_test.csv`) was strictly transformed using the frozen training scaler without updating any statistics.
- **Model Selection Protocol:** Checkpoint `fold_1_seed_303` was selected based exclusively on cross-validation metrics across Records 106 and 119, formally serialized to `results/vqc_model_selection.json`, and documented in `report/vqc_model_selection_protocol.md` before any inference on Records 200 and 208.
- **Zero Leakage Finding:** **VERIFIED (ZERO LEAKAGE DETECTED)**.

### 2.3 Numerical Validity & Reproducibility
- **Optimization Convergence:**
  - Initial loss range: $0.1817 - 0.1985$
  - Final loss range: $0.0638 - 0.0889$ (Mean train MSE: $0.0770$)
  - Function evaluations: Exactly 50 evaluations per run (13 simplex initialization evaluations + 37 trust-region evaluations).
- **Cross-Validation Metrics:**
  - Macro Val Accuracy: $80.00\%$
  - Macro Val F1: $0.7814$
  - Macro Val ROC-AUC: $0.9840$
  - Macro Class Polarity $\Delta p$: $+0.2170$ (Positive across all 10 runs; zero sign inversions).
- **Held-Out Test Metrics:**
  - Test Accuracy: $76.00\%$
  - Test F1: $0.8065$
  - Test Sensitivity: $100.00\%$ (50/50 VEBs detected)
  - Test Specificity: $52.00\%$ (26/50 Normal detected)
  - Test Precision: $67.57\%$
  - Test ROC-AUC: $0.9988$
  - Test ECE: $0.3350$

---

## 3. Disclosures & Scientific Defense

1. **Simulation Scope:** All Phase 5 calculations were executed via Qiskit 2.5.2 `StatevectorEstimator` running exact statevector linear algebra on local CPU hardware. No physical quantum hardware execution was performed (**Execution Status: NOT PERFORMED**).
2. **Benchmark Sensitivity & Operating Point:** On the 100-beat held-out test cohort, the VQC achieved zero false negatives ($100\%$ sensitivity on the 50 test VEB samples). However, this is strictly a retrospective benchmark on MIT-BIH records (200 & 208). It does NOT constitute evidence of clinical safety or diagnostic deployment.
3. **Single-Record Training Disclosure & Record 208 Performance:** Checkpoint `fold_1_seed_303` was trained strictly on Patient Record 106 ($N=100$) and selected based on Record 119 validation performance. It was NOT trained on all 200 samples of the pooled training cohort. Training on a single patient limits exposure to broader patient variations. Record 208 exhibited a higher false-positive rate and lower specificity than Record 200. The difference indicates record-specific distribution shift; its physiological cause has not been established. A separately documented pooled refit on Records 106 and 119 is recommended for future production exploration.
4. **Classical Comparison:** The 12-parameter VQC achieves comparable accuracy ($76\%$ vs $77\%$) and superior ROC-AUC ($0.9988$ vs $0.9864$) compared to a 100-tree Random Forest, demonstrating competitive parameter efficiency on the 6D feature space.

---

## 4. Final Auditor Recommendation

Phase 5 is **APPROVED AND CLOSED**. The engineering team is fully authorized to transition to **PHASE 6: Quantum Hardware Experiments and Processor Architecture Evaluation**.
